The lipid-peptide analog, OK-101 comprises a 12 amino acid peptide sequence, an anchoring lipid domain, and a linker component. It has been developed using a new membrane-anchored peptide
Scemblix specifically targets the ABL myristoyl pocket, which is also called as a STAMP inhibitor in scientific literature. It provides a new treatment approach for patients experiencing intolerance
The vaccine has been authorised for use in adolescents aged 12 to 17 years. The protein-based vaccine, Nuvaxovid is engineered from the genetic sequence of the initial SARS-CoV-2
Ultomiris is a long-acting C5 complement inhibitor that provides immediate, complete and sustained complement inhibition. It is indicated for adult gMG patients, who are anti-acetylcholine receptor (AChR) antibody-positive,
Under the terms of the deal, the company will facilitate access to its monkeypox vaccines in Latin America and the Caribbean, as well as the countries that participate
The monoclonal antibody is being investigated to reduce the risk of major thrombotic cardiovascular events in ESRD patients MK-2060 is a new Factor XI inhibitor and has been designed to
The vaccine has been approved for preventing dengue disease in people aged six years to 45 years. Qdenga has been developed based on a live-attenuated dengue serotype 2
Auvelity is claimed to be the first and only oral N-methyl D-aspartate (NMDA) receptor antagonist with multimodal activity that has been approved to treat MDD. It is said
The regulator has approved Pepaxti in combination with dexamethasone to treat adult multiple myeloma patients who have received at least three lines of therapies previously, whose disease is
The latest move follows a definitive merger agreement signed by the companies for the transaction in June. As announced previously, Bristol Myers Squibb purchased all outstanding shares of
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.